Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

Burnaby, British Columbia, CANADA

VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system is pleased to report that they will be presenting clinical outcome data from Qu’s recently completed Phase 2 study in ulcerative colitis at the inaugural Crohn’s and Colitis Congress in Las Vegas, January 18-20, 2018. This conference is focused on collaborative research solutions and patient-centric approaches to improving the lives of people living with inflammatory bowel disease (IBD). It combines the strength of the leading patient organization, the Crohn’s and Colitis Foundation, with the foremost GI professional organization, the American Gastroenterological Association (AGA).

Poster data will be presented by Jim Pankovich, Qu’s VP Clinical Operations and Drug Development, and includes findings from the Phase 2 trial in ulcerative colitis for their lead immunomodulatory product, QBECO SSI, which targets the gastrointestinal tract. The presentation will focus on the impressive histological and endoscopic response rates found in study participants treated with QBECO SSI.

Mr. Pankovich noted, “Data from this ulcerative colitis study adds to our growing body of promising clinical data in inflammatory bowel disease. It’s particularly encouraging that participants experienced symptom relief, endoscopic, and histological improvements, indicating recovery at a tissue level after treatment with our investigational agent, QBECO SSI. We would like to thank the study participants for their significant contribution to this research program.”

More information about the content of this presentation will be available on the Qu Biologics website and on QuIBD.com post-embargo following the conference.

About Qu Biologics
Qu Biologics is a Vancouver-based private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many conditions including cancer, inflammatory bowel disease, inflammatory lung disease and arthritis. SSIs are a broad platform technology being tested in multiple disease indications, including Health Canada approved clinical trials in lung cancer, Crohn’s disease and ulcerative colitis.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.

For more information regarding this press release, contact:

Hal Gunn, MD
Qu Biologics Inc.
Phone: 604.734.1450 
Email: media@qubiologics.com

Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics’ forward-looking statements due to the risks and uncertainties inherent in Qu Biologics’ business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.